A Phase 1 interventional study of ZN-A-1041 50mg BID and ZN-A-1041 100mg BID in Advanced Solid Tumors and HER2-positive Breast Cancer, sponsored by Suzhou Zanrong Pharma Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Suzhou Zanrong Pharma Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 83 under way, 6 of them phase 3. Brain Neoplasms · China.
Among the 179 studies in Brain Neoplasms with a site in China, this one is the 64th largest by enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2020, is one of 17 in phase 1, and was the 68th registered.
2,442 studies on the registry are indexed under Brain Neoplasms; 543 are open to participants now.
Browse Brain Neoplasms studies →72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Bristol-Myers Squibb · Sites in China, United States, Belgium and 10 more countries
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 76 · Phase 3 22 · Phase 4 3
First in 1997; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 40 across 1,833 interventional studies indexed under Brain Neoplasms.
Median enrollment 60 across the 142 interventional studies, 358 across the 37 observational. Of the 41 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 179 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Suzhou Zanrong Pharma Limited as lead sponsor.
Suzhou Zanrong Pharma Limited has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Brain Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT06457906Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | 2027-08-30 |
| NCT07446842Tongji HospitalConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases | 2026-12 |
| NCT06231186Ruijin Hospitala Feasibility Study of iHD-SRT for BM | 2026-12 |
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 179 studies in Brain Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.
The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).
Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.
Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. In phase 1b, patients with HER2-positive advanced breast cancer (including those with brain metastases) will be enrolled to receive multiple doses of ZN-A-1041 in combination with Capecitabine and Trastuzumab.
In phase 1c patients with HER2-positive breast cancer with brain metastases were planned to be enrolled to receive ZN-A-1041 in combination with Capecitabine and Trastuzumab The dose levels will be determined based on the recommended doses obtained from the Phase 1b study, and the possible changes in the dosage form and the food effect study, which will be decided by the sponsor and the investigator after discussion.
Each phase of the study includes a screening period, a treatment period and a follow-up period. During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination with Capecitabine and Trastuzumab in the subjects will be collected and analyzed, thereby providing RP2D for the subsequent clinical trials.
Key inclusion criteria:
11. performance status of 0 to 1 2. -positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).
3. Phase 1a study will enroll patients with unresectable or HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer.
i. For patients who have no , the following criteria should be met:
1) Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:
iii. In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks.
4. Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases.
i. For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:
Key exclusion criteria:
CNS Exclusion - Based on screening brain MRI and clinical assessment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1a: Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle
Drug: ZN-A-1041 50mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle
Drug: ZN-A-1041 100mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle
Drug: ZN-A-1041 200mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle
Drug: ZN-A-1041 400mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle
Drug: ZN-A-1041 600mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle
Drug: ZN-A-1041 800mg BID
Phase 1a: Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle
Drug: ZN-A-1041 1000mg BID
Phase 1b: ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration
Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Phase 1b: ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration
Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Phase 1b: If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration
Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
Phase 1c: The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion
Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Orally 21days for one cycle
Also known as: ZN-A-1041 Enteric Capsules
Drug page: Bizrolertinib
ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Also known as: ZN-A-1041 Enteric Capsules
Drug page: Bizrolertinib
ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Also known as: ZN-A-1041 Enteric Capsules
Drug page: Bizrolertinib
ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Also known as: ZN-A-1041 Enteric Capsules
Drug page: Bizrolertinib
Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
Also known as: ZN-A-1041 Enteric Capsules
This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.
The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a
Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
Time frame: 23days
The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1b
Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.
Time frame: 21days
The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1c
To evaluate the safety of ZN-A-1041 in combination with Capecitabine in patients on the RP2D Dose
Time frame: through study completion, an average of 3 year
Plasma Level of ZN-A-1041 and its major metabolites on phase 1a,phase 1b and 1c
To assess the AUC of ZN-A-1041 and its major metabolites;
Time frame: From baseline to Day 8
Plasma Level of ZN-A-1041 and its major metabolites on Phase 1a,phase 1 b and 1c
To assess the Cmax of ZN-A-1041 and its major metabolites;
Time frame: From baseline to Day 8
Plasma level of ZN-A-1041 and its main metabolites Phase 1a,phase 1b and 1c
To assess the Tmax of ZN-A-1041 and its major metabolites;
Time frame: From baseline to Day 8
The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c
overall Response Rate (ORR);Progression free survival(PFS)
Time frame: through study completion, an average of 3 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Apr 2024, 42 months.
Of 204 phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 42 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bizrolertinib